1. Introduction {#sec1}
===============

Multipotent mesenchymal stem cells (MSCs) are nonhematopoietic cells of mesodermal derivation residing in several postnatal organs and connective tissues. They were first described in the early 1960s, as an adherent, fibroblastoid cell population with inherent osteogenic properties \[[@B1]\]. Since then, an overwhelming number of studies have demonstrated that MSCs are endowed with a higher plasticity, being able to differentiate into cells of mesenchymal lineages, such as adipogenic, osteogenic, and chondrogenic \[[@B2]\]. MSCs are also capable of transdifferentiation towards epithelial cells, such as alveolar epithelial cells \[[@B3]\], hepatocytes \[[@B4]--[@B7]\], epithelial cells from the gastrointestinal tract \[[@B8], [@B9]\], and kidney cells \[[@B10]\]. The question of possible neural transdifferentiation of MSCs is still debated and controversial \[[@B11]--[@B13]\]. Nonetheless, converging evidence has indicated the capability of MSCs to pursue a functionally and morphologically actual glial fate \[[@B14]--[@B17]\]. The common origin of both mesenchymal cells and neural cells from the neural crest, in the vertebrate embryo, may in part explain the high degree of plasticity of MSCs \[[@B18]\].

Bone Marrow (BM) was originally considered the reference source for MSCs isolation; to date they have been isolated from a multitude of adult tissues, including muscle, adipose tissue, connective tissue, trabecular bone, synovial fluid \[[@B19]\], and perinatal tissues, such as umbilical cord, amniotic fluid, and placenta \[[@B20]--[@B24]\]. In particular, the ubiquity, the ease of retrieval and the minimally invasive procedure required for harvesting the adipose tissue (AT), make it an ideal source for high yield MSCs isolation. Moreover, adipose tissue-derived MSCs (ASCs) can be maintained longer in culture and possess a higher proliferation capacity compared to BM-derived MSCs. Indeed ASCs and BM-MSCs exhibit virtually identical transcription profiles for genes related to the stem cell phenotype, supporting the concept of a common origin of the mesenchymal lineage from a wide variety of tissues \[[@B2], [@B25]\].

2. Fat as a Source of ASCs {#sec2}
==========================

Adipose tissue is a highly complex tissue comprising mature adipocytes (\>90%) and a stromal vascular fraction (SVF), which includes preadipocytes, fibroblasts, vascular smooth muscle cells, endothelial cells, resident monocytes/macrophages, lymphocytes, and ASCs \[[@B26]--[@B28]\]. The density of the AT stem cell reservoir varies as a function of location, type, and species. Within the white fat, a highest number of ASCs reside in subcutaneous depots compared to visceral fat, with the highest concentrations occurring in the arm region and the greatest plasticity described in cells isolated from inguinal AT \[[@B29]\]. Studies in the canine model showed that the proliferative capacity of ASCs appears to inversely correlate with donor age, while stemness, self-renewal, and multipotency are progressively lost with culture passages \[[@B30], [@B31]\]. Moreover, significant differences in molecular profiles and immunophenotype have been described in subcutaneous and visceral fat-derived ASCs \[[@B31], [@B32]\]. The significant sexual dimorphism of adipose tissue distribution and function reflect gender- and hormone-related differences in cellular composition and molecular profiles, which should be taken in due account \[[@B33], [@B34]\]. Finally, ASCs have been described also in brown fat depots and are able to easily undergo skeletal myogenic differentiation \[[@B35], [@B36]\].

3. Isolation and *Ex Vivo* Expansion of ASCs {#sec3}
============================================

Human ASCs can be isolated from adipose tissue collected tissue through liposuction or during reconstructive surgery through resection of tissue fragments. Current methods used for isolating ASCs rely on collagenase digestion followed by centrifuge separation of the SVFs from primary adipocytes. ASCs are selected *in vitro* based on their plastic adherence properties and display typical spindle-shaped fibroblastoid morphology. They can be extensively subcultivated in monolayer culture on standard tissue culture plastics with a basal medium containing 10% of fetal bovine serum \[[@B2], [@B4], [@B37]\].

Once a primary culture is established, ASCs are easily and rapidly expanded *ex vivo* \[[@B2], [@B38]\]. The average frequency of ASCs in processed lipoaspirate is 2% of nucleated cells and the yield of ASCs is approximately 5,000 fibroblast colony-forming units (CFU-F) per gram of adipose tissue, compared with estimates of approximately 100--1,000 CFU-F per milliliter of bone marrow \[[@B39]\], making AT an excellent candidate source for regenerative therapy.

4. Characterization of ASCs {#sec4}
===========================

Although a minimal set of cell surface markers to be analyzed for MSCs identification has been defined in 2006 \[[@B40]\], the correct immunophenotype characterization of ASCs has been debated for a long time. Due to the inherent SVF heterogeneity, a multiparameter flow cytometric analytic and sorting strategy have been developed. Based on the hematopoietic marker CD45, the endothelial marker CD31, the perivascular marker CD146, and the stem-stromal markers CD34, CD90, CD105, and CD117 (c-kit), four distinct populations have been defined in the SVF fraction in uncultured conditions: putative ASCs (CD31−, CD34+/−, CD45−, CD90+, CD105−, CD117− and CD146−), endothelial-progenitor cells (CD31+, CD34+, CD45−, CD90+, CD105−, CD117+ and CD146+), vascular smooth muscle cells or pericytes (CD31−, CD34+/−, CD45−, CD90+, CD105−, CD117+ and CD146+), and hematopoietic cells (CD45+) \[[@B41], [@B42]\]. Studies on whole AT have revealed that the stem/progenitor components, organized around small vessels in an annular fashion, are dominated by a prevalent supra-adventitial layer of CD34+ cells displaying MSCs-like multipotentiality \[[@B41]--[@B43]\]. These supra-adventitial adipose stromal cells (SA-ASC) surround arterioles and venules, which are colonized on their surfaces by CD146+ perivascular cells or pericytes \[[@B42], [@B44]\]. A component of proliferative CD34+ and CD31+ endothelial progenitor cells is associated with the luminal layer \[[@B45]\].

Compared to extensively cultivated ASCs, freshly isolated SVF cells and early passage ASCs express higher levels of CD117 (c-kit), human leukocyte antigen-DR, and stem cell-associated markers such as CD34, along with lower levels of stromal cell markers such as CD13, CD29, CD34, CD54, CD73, CD90, CD105, and MHC I \[[@B46], [@B47]\]. It seems that CD34+ ASCs have a greater proliferative capacity, while CD34− ASCs exert higher plasticity \[[@B48], [@B49]\].

Recently, the International Federation for Adipose Therapeutics and Science (IFATS) and the International Society for Cellular Therapy (ISCT) have provided initial guidance for the scientific community working with adipose-derived cells defining the minimal criteria for the identification of ASCs \[[@B50]\]. In the SVF, cells are identified by the combination of the following markers: CD45−, CD31−, and CD34+. Added information should be given with the analysis of stromal/stem cell markers: CD13, CD73, CD90, and CD105. In culture, like BM-MSCs, ASCs are positive for CD90, CD73, CD105, and CD44, while negative for CD45 and CD31. Unlike BM-MSCs, ASCs are positive for CD36 and negative for CD106. Finally, to allow the identification of ASCs a multilineage differentiation assay should be performed.

5. Osteogenic Potential of ASCs and Their Role in Bone Regeneration {#sec5}
===================================================================

Cell-based approaches for bone formation and regeneration are widely considered the most effective, as they are able to efficiently sustain the physiologic osteogenic process *in vivo*. Indeed, the most promising field for ASCs application is represented by bone reconstruction/regeneration \[[@B38], [@B51]\]. Bones are dynamic organs, undergoing continuous remodeling to maintain tissue homeostasis, modify shape and morphology, and repair fractures \[[@B52]\]. The therapeutic options clinically available are currently restricted to allografts, microvascular bone, and osteomyocutaneous flaps taken from an autologous donor site, and bone distraction for reconstructive purposes \[[@B53]--[@B55]\]. In particular, bone "free flaps" harvested from fibula, scapula, iliac crest, or rib represent the therapeutic gold standard because they contain all the components needed for regeneration, including differentiated bone cells, their cellular precursors, and appropriate growth/differentiation factors. The main disadvantage of this technique relates to the morbidity of the donor site, where a skeletal defect is created. Furthermore, the complexity of autograft procedures raises other technical issues: the maintenance of the arterial and venous flow of the flap in the case of inadequacy of the receiving site (e.g., previous radiation therapy); excessive extension of the bone defect in need of repair; peripheral vasculopathies; and poor general clinical condition \[[@B56]\]. Therefore, scientific research aims to bypass the need for allografts or autologous tissue grafts in repairing large bone defects (either posttraumatic or as a consequence of surgical resection), for which a spontaneous recovery cannot be expected. *In vitro* and *in vivo* models suggest that the use of expanded ASCs improve bone healing through direct differentiation into mature osteoblasts and paracrine effects that facilitate migration and differentiation of resident precursors. The secretome of the SVF \[[@B57], [@B58]\] and of the ASCs \[[@B59], [@B60]\] contains different endocrine factors (adipokines) with bone remodeling activity \[[@B61]--[@B63]\]. Specifically, the vascular endothelial growth factor (VEGF), present in the secretome of both SVF and ASCs, plays a major role in the repair of fractures or bone defects. The VEGF is able to activate the formation of a new network of blood capillaries, which is required during the physiological process of bone regeneration \[[@B64]\]. In addition, VEGF plays a direct role in the recruitment of hematopoietic stem cells leading to the formation of new bone \[[@B65], [@B66]\].

The cell osteogenic potential can be assessed *in vitro*, through an induction assay based on a widely standardized protocol, employing a culture medium supplemented with ascorbic acid, dexamethasone, and beta-glycerol phosphate \[[@B4]\]. Thereafter, to verify the acquisition of an osteogenic phenotype, staining protocols are used to detect calcium deposits and matrix mineralization (namely, Von Kossa and alizarin red methods) \[[@B67]\].

6. ASCs-Based Gene Therapy Osteoinductive Approaches {#sec6}
====================================================

In recent years, cell-based osteoinductive gene-delivery techniques have produced the most convincing results both *in vitro* and *in vivo* models. Such methods use cells genetically-engineered to express selected osteogenic factors to be implanted into the anatomical site where bone regeneration is required. To date, recombinant bone morphogenetic proteins (BMPs) have been the most frequently studied and used osteoinducing agents \[[@B51], [@B68]--[@B74]\]. Lately, several new transcription factors involved in the osteogenic process have been reported, including Runx2, vascular endothelial growth factor (VEGF), the LIM mineralization protein (LMP), Sonic Hedgehog (SHH), and Nell-1 \[[@B56], [@B75]--[@B81]\]. In a study performed by Lee and colleagues \[[@B75]\], BMP-2 and RunX2 were coexpressed in ASCs, demonstrating that BMP2/Runx2-ASCs show a significant increase in bone formation compared to ASCs and BMP2-ASCs. Recently, Zhang et al. \[[@B77]\] studied the osteogenic differentiation of ASCs in presence of VEGF, BMP-6, or VEGF plus BMP-6, showing that the combination of VEGF and BMP-6 significantly enhance the expression of osteospecific genes like Dlx5 and osterix and suggesting a cross-talk between VEGF and BMP-6 signaling pathways during the osteogenic differentiation of ASCs. Also, two pro-osteogenic cytokine, Sonic Hedgehog (SHH) and Nell-1, have been studied by James et al. \[[@B76]\], revealing the additive effects of SHH and NELL-1 on the osteogenic differentiation of ASCs.

7. Scaffolds for ASCs in Bone Repair {#sec7}
====================================

Scaffolds for osteogenesis should mimic bone morphology and structure in order to optimize integration into the surrounding tissue and to provide a suitable microenvironment for MSCs adhesion, proliferation, and differentiation. The micro- and macroarchitecture of the scaffold is known to be highly dependent on the production process \[[@B82], [@B83]\]. A well-characterized biomaterial is hydroxyapatite (HA), Ca~10~(PO~4~)~6~(OH)~2~, which is currently used in clinical applications in different forms. HA is suitable for substituting or integrating diseased or damaged bone tissues since it resembles the mineralized bone phase and supplies fundamental ions for the newly forming bone during resorption \[[@B84], [@B87]\]. Also, beta-tricalcium phosphate (*β*-TCP), Ca~3~(PO~4~)~2~, was thought suitable for clinical use as a carrier for MSCs because of its chemical and crystallographic similarities to the inorganic phase of native bone \[[@B88], [@B89]\]. Biphasic calcium phosphate (BCP) refers to homogenous composites of HA and *β*-TCP \[[@B90]\]. Properties like solubility and resorption capacity of BCP formulations vary widely among different ratios of HA and *β*-TCP. Unfortunately, calcium phosphate ceramics tend to have poor mechanical properties, predisposing them to brittleness and fractures \[[@B91], [@B92]\]. In the last years, several *in vitro* and *in vivo* studies highlight the osteoinductive role of biomimetic scaffold on ASCs \[[@B93], [@B100]\]. In particular, a study performed by Marino and collaborators \[[@B100]\] revealed that *β*-TCP matrix alone is sufficient to trigger the differentiation of ASCs toward an osteoblastic phenotype, regardless of whether the cells are grown in a proliferative or a differentiative medium. Also, Liao et al. \[[@B93]\] compared the osteogenic potential of porcine ASCs (P-ASCs) among three scaffold (polycaprolactone, PCL; polycaprolactone and *β*-tricalcium phosphate, PCL-TCP; collagen I coated-PCL-TCP, PCL-TCP-COL), in order to find an optimal scaffold for bone tissue engineering. The *in vitro* study demonstrated that pASCs display the best osteogenic differentiation rate on PCL-TCP-COL group scaffolds, as demonstrated by the highest ALP activity, osteocalcin expression and mineralization \[[@B93]\]. Also, the experiment in nude mice showed better woven bone and vascular tissue formation in the PCL-TCP-COL group than in the PCL group. In addition, the osteogenic ability of pASCs was found to be enhanced by coating COL onto the PCL-TCP scaffolds, both *in vitro* and *in vivo*. Moreover, Arrigoni et al. \[[@B101]\] compared the neoformed bone tissues achieved by treating critical tibial defects with either hydroxyapatite alone (HA, group I) or hydroxyapatite--autologous ASC constructs (ASCs-HA, group II), investigating their histomorphometric, immunohistochemical, and biomechanical properties. The study displayed that tibial defects treated with rabbit ASCs-HA showed an improved healing process when compared to naked scaffold-treated ones \[[@B101]\].

Calcium-, magnesium-, and silicon-containing ceramics, such as akermanite (Ca~2~MgSi~2~O~7~), show better mechanical properties and degradation rates than other bioceramics and are reported to enhance osteogenic commitment of MSCs \[[@B88], [@B89], [@B102]--[@B104]\]. As shown by Liu and colleagues, human ASCs attachment and proliferation were similar on akermanite and *β*-TCP *in vitro*, and osteogenic ASCs differentiation was enhanced on the akermanite over the *β*-TCP after 10 days of culture \[[@B88]\]. Recently, Zanetti and collegaues observed that ASCs cultured for 21 days in osteogenic medium prior to be seeded onto akermanite-based scaffolds produce greater calcium deposition and osteocalcin expression, compared to cells seeded on *β*-TCP and PCL \[[@B102]\].

Taken together, these data highlight the advantage of using ASCs in combination with biomimetic scaffold providing a most effective strategy for treating bone defects.

8. Dynamic Culture Systems for Cell-Scaffold Constructs {#sec8}
=======================================================

Tissue formation in three-dimensional scaffolds is significantly affected by nutrient transport, physical stress, cell density, and gas exchange \[[@B105], [@B106]\]. For the best possible tissue regeneration, postimplantation cell viability and homogenous cell distribution throughout the scaffold are crucial \[[@B107]\]. Dynamic systems like perfusion bioreactors facilitate optimal seeding under controlled conditions \[[@B107]\]. The term "bioreactor" refers to a wide variety of culture systems that provide a mechanism to maintain cell-scaffold constructs in a biocompatible environment during application of defined chemical and physical stimuli. Perfusion bioreactors are culture systems in which nutrient medium is repeatedly forced or "perfused" through cell-scaffold constructs. Therefore, these are referred to as "dynamic" culture systems in order to distinguish them from "static" cultures in which there is no fluid motion (i.e., standard culture flask or plate). Such culturing systems are aimed at allowing tridimensional cell adhesion on the scaffold and inducing specific cell behavior under controlled and repeatable conditions. This situation mimics a complex natural environment, as the cell-scaffold compound is exposed to common mechanical stimuli, deriving from the shear forces from nutrient medium motion and enables generating constructs with increased functionality and engraftment capacity \[[@B107], [@B108]\].

So far, few studies have described the possibility to establish a 3D culture model for bone cells using mineralized porous scaffolds as templates, which relies on the use of a perfusion-based bioreactor device, highlighting the synergism between a bioactive scaffold and the effect of perfusion on cells and indicating the differentiation into an osteogenic phenotype \[[@B108], [@B115]\]. In particular, in the study by Fröhlich and collaborators \[[@B109]\] ASCs were seeded on decellularized native bone scaffolds, providing the necessary structural and mechanical environment for osteogenic differentiation, and cultured in a perfusion bioreactor. After 5 weeks of culture, the addition of osteogenic supplements (dexamethasone, sodium-beta-glycerophosphate, and ascorbic acid-2-phosphate) to culture medium significantly increased the construct cellularity and the amounts of bone matrix components (collagen, bone sialoprotein, and bone osteopontin), indicating that medium perfusion markedly improved the distribution of cells and bone matrix in engineered constructs \[[@B109]\]. Also, in the study performed by Declercq and colleagues \[[@B110]\], After 6 weeks of dynamic culture, scaffolds were highly colonized and the osteogenic gene expression was higher compared to static cultures. Recently, Silva and colleagues \[[@B111]\] demonstrated that ASCs differentiate towards the osteogenic phenotype when cultured in a bioactive glass scaffold, with the osteogenic Leibovitz L-15 medium and a perfusion bioreactor, as indicated both the significant increase in cell proliferation and viability, the increased ALP activity, and the expression of osteospecific protein (i.e., osteocalcin and osteopontin) 2-to-3 weeks after culture. Furthermore, a coculture model of human osteoblast and endothelial lineage cells has been established by seeding and culturing cells freshly isolated from the SVF of AT within porous 3D ceramic scaffolds \[[@B116]\]. This system was reported to generate 3D constructs that, upon implantation into nude mice, were able to generate bone tissue and fully functional blood vessels \[[@B116], [@B117]\]. Also, a study performed by Güven and colleagues \[[@B118]\] remarks the efficiency of SVF cells to generate 3D-osteogenic constructs, compared to ASCs, supporting the concept that vascular progenitors derived from human SVF cells accelerate the engraftment of critically sized osteogenic constructs, ultimately improving the efficiency and uniformity of bone tissue formation.

9. Preclinical Evaluation of ASC Osteoregenerative Potential {#sec9}
============================================================

A huge amount of data in the literature demonstrates the efficacy of ASC-based approaches for inducing bone regeneration/healing *in vivo*. Critical size-calvarial defects are widely employed to study bone healing in animal models, mostly rodents, allowing an easy quantification of the amount of newly formed bone within a bidimensional defect \[[@B74], [@B119]--[@B138]\]. An initial proof of principle of the *in vivo* osteogenic potential of experimental constructs may be achieved using local intramuscular injection to induce ectopic bone formation \[[@B75], [@B132], [@B139]--[@B144]\]. Also, segmental defects in long bones of large animals are widely used as clinically relevant models, as resembling the fracture healing process \[[@B101], [@B123], [@B94]--[@B157]\].

A number of published report indicates that the combination of recombinant human BMP2 (rhBMP2) with ASC may increase the osteogenic potential *in vivo* (see [Table 1](#tab1){ref-type="table"}), although recent evidences are retracting this consolidated dogma, suggesting that combining rhBMP2 with ASCs, should not be considered the best viable strategy for inducing bone healing.

Overall, the number of published data obtained from animal models employed to study the bone healing properties of ASCs is constantly growing. Although a comprehensive and systematic categorization of all publications on this topic may be quite impossible, [Table 1](#tab1){ref-type="table"} attempts to summarize the study design of relevant preclinical studies. It is noteworthy that successful results, in terms of bone healing, have been achieved in different animal models, using either undifferentiated ASC (i.e., in the absence of any prior *ex vivo* osteogenic induction) \[[@B101], [@B122], [@B125]--[@B127], [@B136], [@B139], [@B142], [@B146], [@B148], [@B150], [@B155]--[@B157]\] or uncultured SVF \[[@B123], [@B134]\] paving the way to an easier translation of preclinical evidence to the clinical setting.

10. Clinical Use of ASCs for Bone Regeneration/Reconstruction {#sec10}
=============================================================

When attempting to translate preclinical evidence to the clinical field, the manipulation of human tissues, for the production of clinical-grade human SVF cells and ASCs to be employed as therapeutic devices, must be carried out according to the current good manufacturing practices (GMP). The national regulatory agencies (i.e., the Food and Drug Administration in USA and the European Medicines Agency in EU) provide the official rules and guidelines that guarantee safe and controlled procedures \[[@B158]\]. In particular, the SVF should be classified as a minimally manipulated tissue, whose isolation does not require seeding and culturing. Conversely, all procedures involving culture-expanded MSC configure advanced cell therapies and must comply with institutional GMP rules for cell manipulation, which must be carried out into a cell factory of a certified facility.

In recent years, ASCs attracted the overwhelming interest of clinicians and industry, being multipotent stem cells endowed with trophic and immune-modulatory properties, residing into a widely available and relatively accessible adult tissue. This has been generating a confusing scenario that often risks to configure clinical misconduct, when putative innovative cell therapies are provided within uncontrolled trials to incorrectly informed patients, in a wide range of clinical applications. On this regard, a useful lesson for "naive" clinicians may be provided by the controversial debate, recently brought by Italian media, around the "Stamina Foundation," which promoted the use of bone marrow-derived MSCs as a "compassionate, as yet-unapproved" treatment of neurodegenerative diseases (including spinal muscular atrophy) in terminally ill children \[[@B161]\]. After all, the proposed protocol for MSC processing, the so called "Vannoni\'s method," was carried out in inappropriate facilities (according to the Italian Medicines Agency, AIFA) and was based on flawed and plagiarized data \[[@B159]\].

In bone reconstructive surgery, autologous or allogeneic bone graft still represents the gold standard treatment although hampered by local morbidity and largely relying on donor availability, expecially in the case of large segments to be harvested. Therefore, the need for alternative procedure has rapidly lead to experimental procedures based on ASCs. Despite the increasing amount of scientific data on ASCs and an extremely wide number of preclinical studies confirming their bone regenerative potential *in vivo*, only few controlled clinical trials, aimed at assessing the efficacy and safety of ASCs in patients with bone-related disorders, have been concluded and published (for review see \[[@B158]\] and \[[@B160]\]) and few others are being currently carried out (<http://www.clinicaltrials.gov/>). In particular, successful results have been obtained in distinct trials using autologous ASC for craniofacial bone reconstruction \[[@B161], [@B162]--[@B164]\].

Lendeckel and colleagues employed ASC for the reconstruction of a large pediatric posttraumatic calvarial defect, which is always challenging and troublesome. In this case, an interdisciplinary surgical equipe implanted a resorbable macroporous sheet as a scaffold for ASC and milled autograft cancellous bone. The complex procedures yielded a stable osteointegrated graft that showed marked ossification at the 3 months followup \[[@B163]\]. Also Thesleff and collaborators used ASCs for calvarial reconstruction, testing alternative biomaterials (*β*-TCP and resorbable mesh bilaminate scaffold), and obtaining successful results in adult patients \[[@B162]\]. Mesimäki and colleagues used autologous ASCs seeded on a beta-tricalcium phosphate (*β*-TCP) scaffold doped with recombinant human BMP2 to treat a large maxillary defect resulting from a benign tumor resection in an adult patient. They achieved satisfactory outcomes, obtaining new, mature, vital, and vascularized bone eight months after surgery, with good osteointegration and stability \[[@B164]\]. More recently, Sandor and colleagues published the successful reconstruction of large anterior mandibular bone defects using ASC seeded on a *β*-TCP premolded scaffold based on patient\'s computed tomography data \[[@B161]\].

The partial drawbacks of experimental ASC-based bone reconstructive procedures are represented by the need to expand cells *ex vivo* for two-to-three weeks to achieve the appropriate cellular yield prior to the implantation, which implies multiple surgical interventions. Moreover, extended *in vitro* ASC expansion may be associated to genomic instability leading to either structural or numeric chromosomal aberrations \[[@B165]\], though it is still unclear whether this may represent a real risk for the recipient patient. Recent research efforts have been spent to develop *ad hoc* devices for the rapid one-step isolation of the SVF from liposuctioned adipose tissue to be grafted without prior *ex vivo* culture amplification manipulation \[[@B166]\]. Further development of such devices may allow overcoming and implementing fat harvesting for ASC isolation aimed at reconstructive surgery.

11. Conclusions {#sec11}
===============

Around 3000 publication surveyed in the scientific databases point towards the definition of ASCs as the most effective and safe cell type for regenerative medicine approaches. Bone regeneration is currently the most promising field for clinical translation of experimental ASCs protocols. Nonetheless, the rapidly growing development of research in the field of biocompatible scaffolds is widening the field of ASCs applications in multidisciplinary scenarios, allowing cells to grow, differentiate, and be exposed to cytokines and growth factors.

###### 

Preclinical studies on ASC osteoregenerative potential.

  Experimental model        Species                             Scaffold/administration              Additional *ex vivo*/*in vivo* treatment   Graft type    Reference
  ------------------------- ----------------------------------- ------------------------------------ ------------------------------------------ ------------- -------------
  Calvarial defect          Rat                                 PLGA                                 Alendronate                                Xenogeneic    \[[@B74]\]
  Rabbit                    HA-PLGA, collagen sponge            BV-BMP2/TGF *β*3                     Allogeneic                                 \[[@B131]\]   
  Mouse                     PLGA                                Dura mater                           Xenogeneic                                 \[[@B128]\]   
  Rat                       *β*-TCP                             Lenti-miR-31                         Allogeneic                                 \[[@B121]\]   
  Mouse                     Custom scaffold                     NOGGIN shRNA-Knockout                Xenogeneic                                 \[[@B130]\]   
  Dog                       HA-PLGA                             None                                 Xenogeneic                                 \[[@B133]\]   
  Mouse                     Systemic injection                  None                                 Allo/xenogeneic                            \[[@B126]\]   
  Mouse                     Local injection                     None                                 Xenogeneic                                 \[[@B127]\]   
  Rat                       DBM, PLA                            None                                 Xenogeneic                                 \[[@B134]\]   
  Rat                       MAP-coated PCL/PLGA                 None                                 Xenogeneic                                 \[[@B122]\]   
  Rat                       HA-*β*-TCP                          None                                 Xenogeneic                                 \[[@B137]\]   
  Rat                       PLGA                                None/osteogenic medium               Xenogeneic                                 \[[@B136]\]   
  Dog                       Coral                               Osteogenic induction                 Autologous                                 \[[@B120]\]   
  Dog                       Coral                               Osteogenic induction                 Allogeneic                                 \[[@B132]\]   
  Pig                       Collagen sponge                     Osteogenic induction                 Autologous                                 \[[@B138]\]   
  Rat                       DBX                                 Osteogenic induction                 Allogeneic                                 \[[@B123]\]   
  Rat                       PCL-PLGA-*β*-TCP                    Osteogenic induction + HUVEC         Xenogeneic                                 \[[@B124]\]   
  Mouse                     pDA-PLGA                            rhBMP-2                              Xenogeneic                                 \[[@B125]\]   
  Rabbit                    Collagen sponge                     rhBMP-2                              Allogeneic                                 \[[@B135]\]   
  Mouse                     HA-PLGA                             Sonic hedgehog signaling Induction   Xenogeneic                                 \[[@B129]\]   
  Rat                       Local injection                     VEGFa                                Xenogeneic                                 \[[@B119]\]   
                                                                                                                                                              
  Ectopic bone formation    Mouse                               PLGA                                 BMP2/RUNX2 bicistronic vector              Xenogeneic    \[[@B75]\]
  Mouse                     PRP + alginate microsphere          None                                 Allogeneic                                 \[[@B142]\]   
  Mouse                     *β*-TCP                             None                                 Xenogeneic                                 \[[@B132]\]   
  Rat                       HA                                  None                                 Xenogeneic                                 \[[@B139]\]   
  Rat                       Matrigel                            Osteogenic induction                 Xenogeneic                                 \[[@B144]\]   
  Rat                       DBM                                 Osteogenic induction                 Xenogeneic                                 \[[@B143]\]   
  Mouse                     Carbon nanotubes                    rhBMP2                               Xenogeneic                                 \[[@B141]\]   
  Rat                       PLDA                                rhBMP2                               Xenogeneic                                 \[[@B140]\]   
                                                                                                                                                              
  Segmental defect          Rabbit                              Local injection                      Bovine BMP                                 Allogeneic    \[[@B145]\]
  Rat                       Fibrin matrix                       rhBMP2                               Allogeneic                                 \[[@B149]\]   
  Rat                       *β*-TCP                             Lenti-BMP2/7                         Allogeneic                                 \[[@B94]\]    
  Rabbit                    PLA/PCL + vascularized periosteum   Ad-Cbfa1                             Allogeneic                                 \[[@B150]\]   
  Rabbits                   HA-PLA-COL                          Ad-hBMP2                             Allogeneic                                 \[[@B147]\]   
                                                                                                                                                              
  Segmental defect          Mouse                               Systemic injection                   None                                       Allogeneic    \[[@B150]\]
  Rat                       Collagen gel                        None                                 Xenogeneic                                 \[[@B155]\]   
  Rabbit                    PLGA                                None/osteogenic medium               Xenogeneic                                 \[[@B123]\]   
  Dog                       *β*-TCP                             None                                 Allogeneic                                 \[[@B148]\]   
  Rabbit                    HA                                  None                                 Autologous                                 \[[@B101]\]   
  Rabbit                    Ceramics, biphasic materials        None                                 Allogeneic                                 \[[@B146]\]   
                                                                                                                                                              
  Vertebral defect/fusion   Mouse                               Local injection                      rhBMP6 nucleofection                       Xenogeneic    \[[@B153]\]
  Rat                       Lyophilized human cancellous bone   Gal-KO + osteogenic induction        Xenogeneic                                 \[[@B152]\]   
  Rat                       Fibrin gel                          rhBMP6 nucleofection                 Xenogeneic                                 \[[@B154]\]   
                                                                                                                                                              
  Mandible defect           Pig                                 Local-systemic injection             None                                       Allogeneic    \[[@B157]\]
  Rat                       HA/COL                              None                                 Xenogeneic                                 \[[@B156]\]   

HA: hydroxyapatite; PLGA: poly(lactic-co-glycolic acid); PLA/PCL: polylactic acid/polycaprolacton; Ad-Cbfa1: adenoviral expression vector carrying the Cbfa1 gene; DBM: demineralized bone matrix; *β*-TCP: beta-tricalcium phosphate; Lenti-miR-31: lentivirus expression vector carrying the microRNA-31; p-DA: polydopamine; PRP: platelet-rich plasma; Lenti-BMP2/7: lentivirus expression vector carrying either the BMP2 or the BMP7 gene, MAP: mussel adhesive proteins, NOGGIN shRNA: short hairpin ribonucleic acid to knockdown NOGGIN gene, COL: collagen; BV-BMP2/TGF *β*3: baculovirus expression vector carrying either the BMP2 or the TGF *β*3 gene, MAP: mussel adhesive proteins; Gal-KP: galactosyl-knock-out; a-CaP: amorphous calcium phosphate; \*these studies were based on uncultured SVF instead of culture-amplified ASCs.

[^1]: Academic Editor: Ji Wu
